Matinas BioPharma shareholders approve issuance of up to 16.9M shares and ratify auditor

Matinas BioPharma Holdings, Inc.

Proposal 1 passed with 88% of votes cast; authorizes up to 16,894,212 common shares upon conversion of Series C Preferred and warrants.
Proposal 2 ratified EisnerAmper LLP as independent auditor for FY2025 with 95% of votes cast.
Proposal 3 to adjourn meeting if needed approved with 90% of votes cast.
Shareholders representing 52.47% of outstanding shares were present at the Special Meeting on April 4, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.